Ubiquinol raises blood levels more efficiently than the older form of coenzyme Q10, but almost all outcome trials used that older form, so the premium buys absorption rather than proven results. The case is strongest for people on cholesterol-lowering drugs, past their fifties with low measured levels, or managing heart or metabolic disease; in healthy adults, benefit is unproven. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Plasma total CoQ10 | 2.5–3.5 µg/mL on therapy; 0.6–1.0 µg/mL untreated | Confirms actual absorption |
| Plasma CoQ10 to total cholesterol ratio | No established target; a clear rise from own baseline | Corrects CoQ10 for the lipoprotein carrying it |
| Blood pressure (home, seated) | 110–120 / 70–80 mmHg | Detects the systolic effect and excessive additive lowering |
| Apolipoprotein B (ApoB) | Below 80 mg/dL; below 60 mg/dL if cardiovascular risk is high | Counts the atherogenic particles ubiquinol is claimed to protect |
| High-sensitivity C-reactive protein (hs-CRP) | Below 1.0 mg/L | Tracks the inflammatory signal CoQ10 reduces |
| Fasting glucose and hemoglobin A1c | Glucose 75–90 mg/dL; A1c 4.9–5.4% | Catches additive lowering with diabetes medication |
| International normalized ratio (INR) | Prescribed target, commonly 2.0–3.0 | Detects the disputed reduction in warfarin effect |
| NT-proBNP | Below 125 pg/mL | Tracks cardiac strain in heart failure |
Cadence: Plasma CoQ10 at 8 weeks; lipid, inflammation and glucose panel at 3 months, then every 6–12 months; home blood pressure daily for a month, then weekly; on warfarin, INR at 1, 2 and 4 weeks after any dose change.